Cinclus Pharma Holding AB (OSTO:CINPHA) ROCE % : -38.94% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cinclus Pharma Holding AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cinclus Pharma Holding AB's annualized ROCE % for the quarter that ended in Dec. 2024 was -38.94%.

Cinclus Pharma Holding AB ROCE % Historical Data

The historical data trend for Cinclus Pharma Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cinclus Pharma Holding AB ROCE % Chart

Cinclus Pharma Holding AB Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

ROCE %

-59.71

-172.74

-576.99

-69.88

Cinclus Pharma Holding AB Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial					-	-	-55.74	-24.90	-38.94

Cinclus Pharma Holding AB ROCE % Calculation

Cinclus Pharma Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-169.638	/	( ( (94.413 - 164.422)	+	(601.013 - 45.493) )	/ 2 )
	=	-169.638	/	( (-70.009	+	555.52)	/ 2 )
	=	-169.638	/	242.7555
	=	-69.88 %

Cinclus Pharma Holding AB's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-227.552	/	( ( (657.724 - 44.38)	+	(601.013 - 45.493) )	/ 2 )
	=	-227.552	/	( ( 613.344	+	555.52 )	/ 2 )
	=	-227.552	/	584.432
	=	-38.94 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Cinclus Pharma Holding AB (OSTO:CINPHA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cinclus Pharma Holding AB ROCE % Related Terms

Thank you for viewing the detailed overview of Cinclus Pharma Holding AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cinclus Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cinclus Pharma Holding AB (OSTO:CINPHA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kungsbron 1, Stockholm, SWE, SE-111 22

Website

https://www.cincluspharma.com

Cinclus Pharma Holding AB is a clinical stage pharmaceutical company developing a drug for the treatment of erosive gastroesophageal reflux diseases, and a dual therapy treatment with an antibiotic targeting Helicobacter pylori which is a bacteria that occurs in the gastric and duodenal mucosa. The Company's main target population is patients suffering from severe eGERD, where there is a lack of satisfactory treatment options.

Cinclus Pharma Holding AB Headlines

No Headlines